Pay in 4 interest-free payments of $13.75 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
non-selective
and improved insulin sensitivity
These data indicates that selective pharmacological inhibition of BCL-2 shows promise for the treatment of BCL-2–dependent hematological cancers
Go6983 was dosed by IV injection to mice bearing B16BL6 tumors at 22 μg per mouse
MI-2 concentrated within human ABC-DLBCL cells and irreversibly inhibited cleavage of MALT1 substrates with EC50 < 1 µM (HBL-1 ~200 nM
CX-4945 - CK2 (Casein Kinase 2) Inhibitor. CAS# 1009820-21-6 Catalog No.:M60267-2S non-selectiveCX 4945 (Silmitasertib), CAS No. 1009820 21 6, is a potent, selective and bioavailable CK2 (Casein Kinase 2) Inhibitor with IC50 of 1 nM. It only inhibits 7 of the 238 kinases by more than 90% at concentration of 0. 5 M, which is 500 fold selectivity over CK2. Although in cell free systems CX 4945 inhibits FLT3, PIM1, and CDK1 with IC50 of 35 nM, 46 nM, and 56 nM, respectively, but it is inactive against FLT3, PIM1, and CDK1 in cell based functional
US$ 106.50
US$ 62.00
US$ 237.00
US$ 262.50
US$ 12.00
US$ 55.00
US$ 100.00